INSM

Over the past six months, Insmed reported its second-quarter 2026 financial results on August 6, 2026, leading to a 33.9% gain in INSM shares. On September 21, 2026, the U.S. FDA accepted Insmed's Supplemental New Drug Application (sNDA) for ARIKAYCE for MAC lung disease, granting it Priority Review with a PDUFA target action date of January 28, 2027, which could expand ARIKAYCE's use. Goldman Sachs initiated coverage on Insmed with a 'Buy' rating and a $188.00 price target on September 24, 2026. BRINSUPRI recently received regulatory approval in Japan and was approved by the European Commission for non-cystic fibrosis bronchiectasis in November 2025. As of September 22, 2026, Insmed's stock was down 31.7% year-to-date, despite a gain over the past 90 days, and has shown high weekly volatility.